TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility in the Prophylaxis of Radiation Dermatitis Severity

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18years~* Undergoing external beam radiotherapy for head/neck cancer at Mayo Clinic Rochester campus.~Note: patients undergoing concurrent chemotherapy are eligible.~* Able to provide informed written consent~* Willing to consent for photography of radiation field~* Receiving a dose ≥ 45 Gy and 20 fractions to both the area being treated and the area being used for comparison~Exclusion Criteria:~* Patients with active rash, pre-existing dermatitis, lupus, tattoos, scleroderma or other conditions within the treatment area that may make skin assessment for the study difficult per treating physician discretion.~* Patients with known allergic and other systemic skin diseases even if not directly affecting irradiated fields.~* Any medical condition that in the opinion of the investigator should exclude him/her from participating in the study.~* Enrolled in an investigational study where product was applied to the proposed study site within 30 days of the screening visit~* The skin area affected by radiation requires treatment with a concomitant medication or product (if applicable)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1- StrataXRT (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must be 19 years of age or older~* Hospitalized with COVID-19 and confirmed via SARS-CoV-2 RT-PCR testing~* Patient is willing and able to provide written consent and comply with all protocol requirements~* Patient agrees to storage of specimens for future testing~Exclusion Criteria:~* Female subjects with positive pregnancy test, are breastfeeding or planning to become pregnant/breastfeed during the study period~* Symptomatic illness exceeding 14 days from onset of illness at time of enrollment~* ICU admission on initial presentation at the hospital (includes patients with clinical indications for ICU admission as follows:~  1. Respiratory distress with requirement of O2 \>6 lpm to maintain O2 sat \>92%~ 2. Rapid escalation of O2 requirement/significant work of breathing~ 3. Hemodynamic instability: SBP \<90, MAP \<65~* Receipt of any blood products including pooled immunoglobulin or intravenous immunoglobulin (IVIg) in the past 30 days prior to enrolment~* Known IgA deficiency~* Presence of any contraindication to transfusion (or history of prior severe reactions to transfusion of blood products)

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anti-SARS-CoV-2 convalescent plasma (Type: EXPERIMENTAL): About 500 mL of type-specific anti-SARS-CoV-2 convalescent plasma collected by whole blood donation or standard pheresis from a volunteer who recovered from COVID-19 transfused intravenously as 2 aliquots of 250 mL
- Standard of care (Type: NO_INTERVENTION): Patients in the control group are those will only receive local standard of care as deemed appropriate by the primary attending physicians and guided by institutional pathways

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bipolar 15 Charrières Office Resectoscope : Polypectomy Without Anesthesia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients aged 18 or over~* Patients with 1 to 2 endometrial polyps~* Polyps diagnosed by ultrasound and / or diagnostic hysteroscopy following a check-up for menometrorrhagia, infertility or during a check-up~* Polyps measuring less than 3 cm~* Have signed a consent form~* Be affiliated with a Health Insurance plan.~Exclusion Criteria:~* Pregnant or lactating patient~* Cervical stenosis~* Patient having more than 2 polyps~* Polyps measuring 3 cm or more~* Malignant cells on histology~* Associated indication of endometrectomy or other endo-uterine gesture~* Hypersensitivity to remifentanil or to other fentanyl derivatives or to any of the excipients of the specialty used~* Hypersensitivity to propofol or to any of the excipients of the specialty used~* Cardiac pathology~* Diaphragmatic hernia~* Morbid obesity (BMI\> 35)~* Invasive cervical cancer~* Chronic obstructive pulmonary disease~* Patient presenting a strictly greater than 4 on a pain scale (from 0 to 10) during a diagnostic hysteroscopy~* Does not speak and / or understand French~* Be deprived of liberty or under guardianship.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Polypectomy without anesthesia or analgo-sedation (Type: EXPERIMENTAL): Patient will undergo polypectomy without anesthesia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Inheritance of Osteosarcoma & Paget's Disease Through Chromosome 18:

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: FAMILY_BASED
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* This is a familial study therefore the only inclusion/exclusion criteria would be that subjects must be a blood relative and over the age of 18.~* The subjects are proband and father along with unaffected blood relatives. Their peripheral blood will act as a control and provide information to delineate the inheritance from the father, as seen in the son.~Exclusion Criteria:~* Not part of the family

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- family members (Type: None): family members of the proband and father identified

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of an Early Wheelchair Reconditionong Program on Functional Independence in Spinal Cord-inured Individuals

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Acute spinal cord injury (SCI) from trauma , medical or surgical pathology at levels between C7 and L1.~* Categories A or B as defined by the American Spinal Injury Association (ASIA) Impairment Scale~* Male or female~* 18 to 60 years old.~* No ability to walk independently with or without an assistive device~* 3 to 6 months post-SCI in early phase of rehabilitation in a physical medicine and rehabilitation unit.~* Subject affiliated to a social security regime and registered at the healthcare department~* Written informed consent obtained from each subject~Exclusion Criteria:~* Symptomatic syringomyelia that may complicate the evaluation procedures~* Disabled pathology before the SCI~* Cardiopulmonary disease, degenerative disorders, upper limb disorders, bones inury or other significant medical complications that would prohibit or alter compliance with a wheelchair training protocol.~* Psychological incapacity to follow a training protocol during 8 weeks.~* Surgery or intrathecal injection planned.~* Reject to give written informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- control (Type: None): group with classical rehabilitation program
- training (Type: None): group with an 8 weeks interval training program on wheelchair independence

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Health Economics Evaluation of Percutaneous Vertebroplasty Compared to Radiation Therapy in Patients With Painful Spine Metastases.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years at the day of consenting to the study~* Patient with at least a painful spine metastasis confirmed by MRI / CT scan,~* Localized pain at the lesion ≥ 4 (VAS),~* Bone axial metastasis localised on ≤ 6 different vertebrae,~* Histologically established diagnosis of cancer (lung, kidney, breast, prostate, melanoma, soft tissue sarcomas) other than hematologic malignancy, myeloma, brain tumor, germ cell tumor and bone sarcomas~* ECOG performance status 0 to 2 (Appendix 2)~* Minimum life expectancy of 6 months (Tokuhashi score \> 8 )~* Ability to understand and willingness for follow-up visits.~* Covered by a medical insurance~* Signed and dated informed consent document indicating that the patient has been informed of all the pertinent aspects of the trial prior to enrolment~Exclusion Criteria:~* Solitary metastasis~* SBRT indication~* Contra-indication to vertebroplasty~* Previous radiotherapy for pain management in the same area.~* Patient unable to lie prone~* Neurological deficit due to spinal cord compression,~* Active infection,~* Bleeding risk (platelets \< 50000 and PTT \> 1.5\*ULN),~* Risk of vertebral collapse (SINS score ≥ 13),~* Impossible follow-up for social, geographical, familial or psychological reasons,~* Patient deprived of freedom,~* Patient enrolled in another experimental surgical trial, with therapeutic endpoint,~* Pregnant or breastfeeding women,Pregnant or breastfeeding women (mandatory negative serum or urinary pregnancy test at study entry for all women of childbearing potential

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Percutaneous vertebroplasty
- Arm B (Type: EXPERIMENTAL): External radiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intra-articular Local Anesthetic Injection and Hematoma Aspiration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with isolated tibial plateau fractures aged 18 years and older~* Patients with tibial plateau fractures and associated soft tissue complaints about the knee, not associated with a fracture outside of the tibial plateau~* Patients with bilateral tibial plateau fractures and no other noted fractures~Exclusion Criteria:~* Any patient that does not wish to participate in the study or is unable to give consent at the initial encounter~* Patients under 18 years old~* Pregnant patients~* Patients who are unable to understand the study procedures~* Incarcerated patients~* History of allergic reaction to local anesthetics~* Emergent conditions requiring operations or airway protection~* Polytrauma patients~* Patients presenting for care greater than 24 hours following their injury.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aspiration (Type: EXPERIMENTAL): Participants assigned to this arm receive aspiration of the joint alone in which a needle will be introduced into the knee joint to withdraw the blood that collects within the knee.
- Aspiration with injection (Type: EXPERIMENTAL): Participants assigned to this arm receive aspiration of the knee joint and an injection of 20cc bupivacaine 0.5% with 1:200,000 epinephrine
- Control (Type: NO_INTERVENTION): Participants assigned to this arm receive no injection or aspiration therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Nasopharyngeal Pressure Measurement During Neonatal Nasal Respiratory Support

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Any infant admitted to neonatal intensive care who is treated with a modality of non-invasive respiratory support, such as low or high flow nasal cannula; nasal prong, catheter or mask continuous distending pressure; or nasal ventilation either intermittent mandatory, synchronized or high frequency will be eligible for study.~Exclusion Criteria:~* Patients with oral, nasal, or palatal deformities who can not otherwise be fitted with cannula or mask will be excluded from the study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 72 Hours
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Parnaparin vs Aspirin in the Treatment of Retinal Vein Occlusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 and 85 years~* A body weight of greater than 50 Kg~* A requirement that no more than 15 days had passed between symptomatic presentation, confirmation of RVO and entry into the study.~Exclusion Criteria:~* Modification of the optic media transparency that could compromise the evaluation of fluorescein angiography, such as cataract or corneal degeneration~* History of major ocular surgery (with the exclusion of cataract extraction)~* Previous RVO~* Other ocular conditions that, in the opinion of the investigator, could have affected macular edema or altered visual acuity during the course of the study - Contraindications to the study drugs (e.g. major bleeding or neurosurgical procedures in the previous 3 months, serum creatinine levels of greater than 2.0 mg/dL, severe liver insufficiency, platelet count \< 100,000 mm3, known active peptic gastric ulcer)~* Active malignancy~* Pregnancy~* Inability to attend for follow up or anticipated non-compliance~* Ongoing treatment with aspirin or anticoagulant drugs at the time of RVO diagnosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): parnaparin, low molecular weight heparin
- 2 (Type: ACTIVE_COMPARATOR): aspirin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Surveillance Versus Aortic Endografting for Small Aneurysm Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of 50-80 years of age~* Non symptomatic infrarenal AAA of 4.1 to 5.4 cm in diameter measured by CT performed within 3 months before randomization~* Adequate infrarenal aortic neck (length \> 15 mm diameter \< 30 mm) and other anatomical configurations suitable for EVAR~* Patients have a life expectancy of at least 5 years~* Signed informed consent~Exclusion Criteria:~* Ruptured or symptomatic AAA~* AAA maximum diameter \>= 5.5 cm~* Suprarenal or thoracic aorta aneurysm of more than 4.0 cm~* Patient unsuitable for administration of contrast agent~* Severe heart, lung, liver or renal disease (serum creatinine \>= 3mg/dl)~* Need for adjunctive major surgical or vascular procedures within 1 month~* High likelihood of non compliance with follow-up requirements

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- EVAR (Type: EXPERIMENTAL): AAA repair with endografting
- Surveillance (Type: ACTIVE_COMPARATOR): Not AAA repair; surveillance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Characterization and Epigenetics of Post-Partum Preeclampsia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Post partum pre-eclampsia~Matching based on:~* maternal age (years +/-3)~* BMI (+/-5 points)~* Ethnicity~* Mode of delivery~* Gestational age at delivery (+/7 days)~* Smoking status~Exclusion Criteria:~* Intrapartum pre-eclampsia

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- post partum pre-eclampsia (Type: None): women with normal deliveries followed by post partum pre-eclampsia within 1 month of delivery.
- controls (Type: None): women with normal deliveries and normal post part courses who match the post partum pre-eclampsia women in age, BMI, smoking status, gestational age and race/ethnicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a diagnosis of cancer , and no history of peripheral neuropathy~* Have had the appropriate surgery for carcinoma and are no more than 12 weeks post-operatively at study entry~* Have not received chemotherapy (chemotherapy naïve patients) and are scheduled to receive at least 4 cycles of combination taxane and platinum-based chemotherapy~* Have a hemoglobin value of \>= 10 and \< 12 g/dL~* have a life expectancy of at least 6 months~Exclusion Criteria:~* Patients who have had prior treatment with PROCRIT (epoetin alfa) or similar drugs (erythropoietic agents) within the last 2 months~* Have used experimental treatments within the last year that are reported or hypothesized to have neuroprotective potential, including amifostine, cyanocobalamin (vitamin B12), alpha-tocopherol (Vitamin E), glutamine, and gabapentin~* have anemia due to factors other than cancer/chemotherapy, or have ongoing neuropathy due to any cause~* Received a transfusion of platelets or packed red blood cells within 28 days prior to the first dose of study medication~* Have a history of pulmonary emboli, deep vein thrombosis, ischemic stroke or any other history of arterial or venous thrombotic events

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): PROCRIT 40 000 IU QW Epoetin alpha (PROCRIT) 40 000 IU every week (QW) for 18 weeks (IV or SC)
- 002 (Type: PLACEBO_COMPARATOR): Placebo Equivalent volume to PROCRIT (1 mL) administered (QW) for 18 weeks (IV or SC)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Radical Cystectomy: Can We Improve Our Surgical Technique With the Ligasure Impact Tissue-Sealing Device?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Muscle invasive bladder cancer~* Male/Female gender~Exclusion Criteria:

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Stapling device (Type: ACTIVE_COMPARATOR): Efficacy of stapling device during radical cystectomy
- Ligasure Device (Type: ACTIVE_COMPARATOR): Efficacy of ligasure tissue sealing device during radical cystectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Characteristics of Cord Blood Immunologic Parameters of Infants <32 Weeks Gestation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Infants born at Children's Memorial Hermann Hospital with cord blood available \< 1500gm or \< 32 weeks gestation by OB estimate~Exclusion Criteria:~* Outborn infants transferred to CMHH without cord blood available~* Parents to not consent~* \> 1500gm or \> 32 weeks gestation by OB estimate

- Gender: ALL
- Minimum Age: None
- Maximum Age: 3 Days
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility